New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis

Lluís Puig Sanz, Elena Carmona Rocha, Lluís Rusiñol

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

1 Citació (Scopus)


The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modulator) and roflumilast (a PDE-4 inhibitor) have exhibited favorable efficacy and safety outcomes and have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis, especially those that are currently under evaluation and development for the treatment of psoriasis.
Idioma originalEnglish
Número d’article239
Estat de la publicacióPublicada - 6 de febr. 2024


Navegar pels temes de recerca de 'New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis'. Junts formen un fingerprint únic.

Com citar-ho